Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Makucell is a biotechnology company focused on the development of science-based skincare and regenerative medicine products. Founded on research from the University of Southern California, the company leverages the Wnt signaling pathway to stimulate the body's natural stem cells for skin repair and rejuvenation. Their primary commercial offering was the Renewnt line of cosmeceuticals, which utilized a proprietary small molecule to address signs of aging and photo-damage. While primarily focused on the consumer skincare market, the underlying technology was designed with potential applications in wound healing and hair follicle regeneration. The company's approach centered on 're-booting' the skin's natural ability to heal itself by activating specific molecular pathways. Despite its innovative scientific foundation, the company appears to be currently inactive.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Makucell.